2014


To access this material please log in or register

Register Authorize
2014/№1

Galectin-3: Clinical and predictive value in patients with chronic heart failure

Gyamdzhyan K. A., Drapkina O. M., Maksimov M. L.
State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bldg. 2, Moscow 119991

Keywords: biomarkers, galectin-3, diagnostics, CHF

DOI: 10.18087/rhfj.2014.1.1898

The article provides a review of studies focused on measuring plasma levels of galectin-3 as a marker for CHF.
  1. Агеев Ф. Т., Арутюнов Г. П., Беленков Ю. Н. и др. Хроническая сердечная недостаточность. – М., "ГЭОТАР-Медиа", 2010. –336 с.
  2. Ho JE, Liu C, Lyass A et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60 (14):1249–1256.
  3. Максимов М. Л. Влияние кардиоселективного бета-блокатора небиволола на глобальную и локальную сократимость миокарда у больных ишемической болезнью сердца, осложненной хронической сердечной недостаточностью. Автореферат диссертации кандидата медицинских наук. – Москва, 2004.
  4. Агеев Ф. Т., Азизова А. Г. Галектин-3 – новый биохимический маркер сердечной недостаточности. Журнал Сердечная Недостаточность. 2011;12 (2):108–114.
  5. Драпкина О. М., Дуболазова Ю. В. Применение биологических маркеров в диагностике диастолической сердечной недостаточности. Журнал Сердечная недостаточность. 2011;12 (6):364–372.
  6. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Reasearch Reports in Clinical Cardiology 2013:4:13–12.
  7. Kim H, Lee J, Hyun JW et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int. 2007l;31 (7):655–662.
  8. Ochieng J, Leite-Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 1998;246 (3):788–791.
  9. Karlsson A, Christenson K, Matlak M et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology. 2009;19 (1):16–20.
  10. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activa­ted macrophages in failure-prone hypertrophied hearts and contri­butes to cardiac dysfunction. Circulation. 2004;110 (19):3121–3128.
  11. Schroen B, Heymans S, Sharma U et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res. 2004;95 (5):515–522.
  12. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006;103 (13):5060–5065.
  13. Liu YH, D'Ambrosio M, Liao TD et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion / growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296 (2):H404–412.
  14. Calvier L et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Atheroscler Thromb Vasc Biol. 2013;33 (1):67–75
  15. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7 (1):1–8.
  16. van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48 (6):1217–1224.
  17. Дуболазова Ю. В. Оценка клинического течения хронической сердечной недостаточности с сохраненной фракцией выброса. Автореф. дисс…. канд. мед. наук. – Москва. 2012. –24
  18. Gullestad L, Ueland T, Kjekshus J et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012;33 (18):2290–2296.
  19. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin i in older patients with systolic heart failure. N Engl J Med. 2007;357 (22):2248–2261.
  20. Cohn JN, Tognoni G. A randomized trial of the angiotensin – receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345 (23):1667–1675.
  21. Anand IS, Rector TS, Kuskowski M et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15 (5):511–518.
  22. Milting H, Ellinghaus P, Seewald M et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27 (6):589–596.
  23. Erkilet G, Schulte-Eistrup S, Morshuis M et al. Plasma galectin 3 is increased in terminal heart failure patients and is elevated in patients not surviving mechanical circulatory support. J Heart Lung Transplant. 2010;29 (2):S65.
  24. Lopez-Andrès N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dyssynchrony: insights from CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012 Jan;14 (1):74–81.
  25. Lok DJ, Lok SI, Bruggink-André de la Porte PW et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102 (2):103–110.
  26. Felker GM, Fiuzat M, Shaw LK et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012;5 (1):72–78.
  27. Lok DJ, Van Der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99 (5):323–328.
  28. Erkilet G, Özpeker C, Böthig D et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant. 2013;32 (2):221–230.
  29. de Boer RA, Lok DJ, Jaarsma T et al. Predictive values of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43 (1):60–68.
  30. Shah RV, Chen-Tournoux AA, Picard MH et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12 (8):826–832.
  31. de Boer RA, van Veldhuisen DJ, Gansevoort RT et al. The fibrosis marker galectin-3 and outcome in general population. J Intern Med. 2012;272 (1):55–64.
  32. Biomarker Definitions Working Group. Biomarkers and surrogate end-points: preffered definitions and conceptual framework. Clin Pharmacol Ther. 2001;69 (3):89–95.
Gyamdzhyan K. A., Drapkina O. M., Maksimov M. L. Galectin-3: Clinical and predictive value in patients with chronic heart failure. Russian Heart Failure Journal. 2014;15(1):51–55

To access this material please log in or register

Register Authorize
Ru En